产品名称
苯丙氨酸, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1
SMILES string
N[C@@H](Cc1ccccc1)C(O)=O
InChI key
COLNVLDHVKWLRT-QMMMGPOBSA-N
grade
pharmaceutical primary standard
API family
phenylalanine
manufacturer/tradename
EDQM
mp
270-275 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Sohei Nakayama et al.
Cancer research, 74(20), 5891-5902 (2014-08-29)
The discovery of somatic mutations in EGFR and development of EGFR tyrosine kinase inhibitors (TKI) have revolutionized treatment for lung cancer. However, resistance to TKIs emerges in almost all patients and currently no effective treatment is available. Here, we show
John J Mitchell et al.
Genetics in medicine : official journal of the American College of Medical Genetics, 13(8), 697-707 (2011-05-11)
Phenylalanine hydroxylase deficiency is an autosomal recessive disorder that results in intolerance to the dietary intake of the essential amino acid phenylalanine. It occurs in approximately 1:15,000 individuals. Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria
Christineh N Sarkissian et al.
Molecular genetics and metabolism, 86 Suppl 1, S22-S26 (2005-09-17)
Phenylketonuria (PKU) is an autosomal recessive genetic disorder in which mutations in the phenylalanine-4-hydroxylase (PAH) gene result in an inactive enzyme (PAH, EC 1.14.16.1). The effect is an inability to metabolize phenylalanine (Phe), translating into elevated levels of Phe in
Marte I Flydal et al.
IUBMB life, 65(4), 341-349 (2013-03-05)
Mammalian phenylalanine hydroxylase (PAH) catalyzes the rate-limiting step in the phenylalanine catabolism, consuming about 75% of the phenylalanine input from the diet and protein catabolism under physiological conditions. In humans, mutations in the PAH gene lead to phenylketonuria (PKU), and
Rianne Jahja et al.
The Journal of pediatrics, 164(4), 895-899 (2014-02-04)
To compare the neurocognitive outcomes of patients with phenylketonuria (PKU) to determine whether decreasing phenylalanine (Phe) levels to <240 is preferable to the use of 360 μmol/L as an upper-target Phe level. An additional aim was to establish the influence of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持